Leerink Partners Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target lifted by Leerink Partners from $45.00 to $52.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

TEVA has been the topic of several other research reports. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Barclays lifted their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. HC Wainwright assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Monday. They set a “buy” rating and a $52.00 price target on the stock. Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Finally, UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $47.23.

Teva Pharmaceutical Industries Trading Down 0.4%

TEVA opened at $41.68 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $23.61 and a 52 week high of $43.34. The business has a fifty day simple moving average of $39.39 and a 200-day simple moving average of $34.73. The firm has a market cap of $48.57 billion, a P/E ratio of 18.52, a P/E/G ratio of 3.92 and a beta of 0.97. The company has a quick ratio of 0.67, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 earnings per share. On average, equities analysts expect that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. The trade was a 46.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The SEC filing for this sale provides additional information. 0.54% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC raised its stake in Teva Pharmaceutical Industries by 8.7% in the third quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock valued at $183,000 after buying an additional 370 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in Teva Pharmaceutical Industries by 7.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock worth $248,000 after buying an additional 483 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Teva Pharmaceutical Industries by 5.9% during the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock worth $290,000 after acquiring an additional 539 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after acquiring an additional 647 shares in the last quarter. Finally, Victrix Investment Advisors boosted its position in shares of Teva Pharmaceutical Industries by 9.5% during the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock worth $266,000 after acquiring an additional 681 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva beat Q3 earnings estimates, with strong branded-drug sales supporting results. The company also raised its 2026 revenue and product-sales outlook, a signal of improved expectations for the business. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: Analyst sentiment strengthened: Leerink Partners raised its target to $52 and assigned an “Outperform” rating, while TD Cowen lifted its target to $57 and maintained a “Buy” rating. HC Wainwright also rates the shares “Buy” with a $52 target; it projects FY2027 EPS of $3.03. Tickerreport.com analyst update
• Positive Sentiment: A deal with Samsung Bioepis is reported to expand Teva’s U.S. drug portfolio, potentially adding to its product opportunities. Teva expands US drug portfolio in Samsung Bioepis deal
• Neutral Sentiment: MindWalk announced an agreement with Teva Australia to support defined antibody-discovery workflows. The report does not specify the deal’s financial contribution. MindWalk Announces Agreement with Teva Australia
• Negative Sentiment: One report noted that Q3 revenue slipped, which tempers the earnings beat; investors will look for the raised 2026 outlook to translate into sustained growth. Teva stock: Q3 revenue slips as 2026 outlook rises

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.